No Prescription |
 |
 | ||
|
Prescription Drugs 5 |
|
| ||
No Prescription » Prescription Drugs 5
Cordarone X Generic Amiodarone Cosopt Eye Drops GB Generic Dorzolamide Timolol Cosopt Generic Dorzolamide hydrochloride and Timolol Cyclo Progynova Generic Estradiol valerate Cyclogyl Eye Drops Generic Cyclopentolate Hydrochloride Cyclospasmol Generic Cyclandelate Cyklokapron Generic Tranexamic acid DA Double Advantage For Dogs 10kg 25kg K9 Advantix 55 DA Double Advantage For Dogs 4kg to 10kg K9 Advantix 55 Daktacort Topical Cream Generic Miconazole Daktarin Oral Gel Generic Miconazole Deltacortril Generic Prednisolone Depakote DR Generic Divalproex Depo provera Generic Medroxyprogesterone Dermol Scalp Application Solution Temovate Dermovate scalp lotion Generic Clobetasol 17 propionate Desmopressin PH T Nasal Spray Generic Stimate Dexamethasone Generic Decaderm
No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
|
|
|